Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
STABILITY OF HER-2 NEU EXPRESSION OVER TIME AND AT MULTIPLE METASTATIC SITES/
Autore:
NIEHANS GA; SINGLETON TP; DYKOSKI D; KIANG DT;
Indirizzi:
UNIV MINNESOTA,SCH MED,DEPT LAB MED & PATHOL,BOX 168 UMHC,HARVARD ST & E RIVER RD MINNEAPOLIS MN 55455 UNIV MINNESOTA,SCH MED,DEPT LAB MED & PATHOL,BOX 168 UMHC,HARVARD ST & E RIVER RD MINNEAPOLIS MN 55455 UNIV MINNESOTA,SCH MED,DEPT MED,DIV MED ONCOL MINNEAPOLIS MN 55455 DEPT VET AFFAIRS MED CTR,LAB SERV MINNEAPOLIS MN 00000
Titolo Testata:
Journal of the National Cancer Institute
fascicolo: 15, volume: 85, anno: 1993,
pagine: 1230 - 1235
Fonte:
ISI
Lingua:
ENG
Soggetto:
HUMAN-BREAST-CANCER; DUCTAL CARCINOMA INSITU; GROWTH-FACTOR RECEPTOR; NEU ONCOGENE; EXTRACELLULAR DOMAIN; C-ERBB-2 ONCOGENE; TUMOR-CELLS; IMMUNOHISTOCHEMICAL EVALUATION; PROTEIN OVEREXPRESSION; MONOCLONAL-ANTIBODIES;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
58
Recensione:
Indirizzi per estratti:
Citazione:
G.A. Niehans et al., "STABILITY OF HER-2 NEU EXPRESSION OVER TIME AND AT MULTIPLE METASTATIC SITES/", Journal of the National Cancer Institute, 85(15), 1993, pp. 1230-1235

Abstract

Background: Amplification and over-expression of the HER-2/neu oncogene (also known as c-erbB-2) occurs in 20%-30% of invasive breast carcinomas. The extent to which HER-2/neu expression changes over time in association with tumor progression or is heterogeneous at different metastatic sites has received only limited study. Purpose: Our purpose was to determine whether primary tumors differ from metastases in HER-2/neu protein content or whether metastases are heterogeneous in regard to HER-2/neu expression. Methods: In a retrospective study, we examined tumor tissue obtained at autopsy from two to rive metastatic organ sites in each of 30 patients who died with metastatic breast carcinoma. Using an immunoperoxidase technique, we stained archival formalin-fixed, paraffin-embedded tissue sections with a monoclonal antibody to the 185-kilodalton protein product (p185) of the HER-2/neu gene. Results: The tissue from eight of 30 patients showed strong diffuse reactivity for p185 at all metastatic sites examined. Tissues from six patientsshowed faint staining and tissues from 15 were negative, again with acongruent staining pattern. A single case showed discordant staining,in that two of four metastases showed faint staining, whereas the other two showed strong immunoreactivity. In 14 cases, we were able to obtain paraffin blocks from the original biopsy or surgical resection ofthe primary breast lesion. For these 14 patients, the average length of time between initial diagnosis and death was 4 years (range, 2-9). There was good correlation between results from autopsy and original surgical tissues. Conclusions: Expression of HER-2/neu appears to be relatively stable over time and is generally congruent at different metastatic sites. Implications: The fact that p185 immunoreactivity is rarely heterogeneous is encouraging, both for the potential use of HER-2/neu-related proteins as serum tumor markers and for innovative therapies targeted at p185 expression.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/09/20 alle ore 19:42:22